iTRAQ-Based Quantitative Proteomics Reveals the Energy Metabolism Alterations Induced by Chlorogenic Acid in HepG2 Cells

Shoko Takahashi, Kenji Saito, Xuguang Li, Huijuan Jia * and Hisanori Kato

Health Nutrition, Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan; takahashi@genequest.jp (S.T.); skkj774@gmail.com (K.S.); lixuguang1225@gmail.com (X.L.); akatoq@g.ecc.u-tokyo.ac.jp (H.K.)

* Correspondence: akakeiken@g.ecc.u-tokyo.ac.jp; Tel.: +81-3-5841-5116

Abstract: Epidemiological studies have suggested that coffee consumption is associated with a decrease in the risk of developing obesity and diabetes; however, the detailed mechanisms underlying these effects of coffee consumption remain poorly understood. In this study, we examined the effects of chlorogenic acid on energy metabolism in vitro. Hepatocellular carcinoma G2 (HepG2) cells were cultured in a medium containing chlorogenic acid. Chlorogenic acid increased the activity of mitochondrial enzymes, including citrate synthase, isocitrate dehydrogenase, and malate dehydrogenase (MDH), which are involved in the tricarboxylic acid (TCA) cycle. Proteome analysis using the isobaric tags for the relative and absolute quantitation (iTRAQ) method revealed the upregulation of proteins involved in the glycolytic system, electron transport system, and ATP synthesis in mitochondria. Therefore, we propose a notable mechanism whereby chlorogenic acid enhances energy metabolism, including the TCA cycle, glycolytic system, electron transport, and ATP synthesis. This mechanism provides important insights into understanding the beneficial effects of coffee consumption.

Keywords: coffee; chlorogenic acid; energy metabolism; lipid metabolism; HepG2 cells; proteomics

1. Introduction

Coffee has been consumed by humans for thousands of years and is currently one of the most popular beverages worldwide. Accumulating epidemiological evidence suggests that coffee, as a functional food, plays a role in the prevention of diseases. Therefore, understanding the effects of coffee intake on health is desirable. Lines of evidence, including those from epidemiological studies, have suggested that the intake of coffee may reduce the risk of developing obesity and diabetes \[1,2\]. A meta-analysis of prospective cohort research [3] revealed that the intake of coffee ingredients helped decrease the risk of type 2 diabetes. However, the detailed mechanisms underlying the beneficial effects of coffee consumption are still poorly understood.

Many studies on the effects of coffee have focused on liver tissue, including a meta-analysis of four cohort studies by Larsson and Wolk [4], which revealed that consuming two cups of coffee per day decreased the risk of hepatic cancer by 43%. The effects of coffee ingredients on hepatic cells have been examined in several studies, some of which used human hepatocellular carcinoma G2 (HepG2) cells to explore the physiological action of coffee ingredients. HepG2 cells are considered a feasible model for in vitro analysis of xenobiotic metabolism and hepatotoxicity since they perform the majority of the physiological functions like normal human hepatocytes \[5,6\]. For example, Riedel et al. [7] studied the effects of trigonelline on hepatic glucose metabolism, while Vyayshteyn and Jeong [8] and Kalhoff et al. [9] reported the effects of caffeine on the expression of cytochrome P450 1A2 (CYP1A2) and glucuronosyltransferase in HepG2 cells, respectively. Since coffee ingredients and/or their metabolites remain in the blood after the coffee is consumed, the

https://creativecommons.org/licenses/by/4.0/.

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Nutrients 2022, 14, 1676. https://doi.org/10.3390/nu14081676 https://www.mdpi.com/journal/nutrients
findings of these in vitro studies using coffee ingredients could shed some light on the bioactivity of coffee. As a model of metabolically active cells, HepG2 was also used in this experiment.

Our previous in vivo studies, conducted with multi-omics analyses (transcriptomics, proteomics, and metabolomics), suggested that coffee intake activates the urea cycle and the tricarboxylic acid (TCA) cycle in the livers of C57BL/6j mice fed a high-fat diet [10,11]. To the best of our knowledge, there have been no studies on the effects of coffee ingredients and hepatic energy metabolism in cultured hepatic cells. In the present study, we explored the effects of coffee and chlorogenic acid (CGA) on energy metabolism in an in vitro experiment using HepG2 cells.

2. Materials and Methods

2.1. Cell Culture

Human hepatocyte HepG2 cells (American Type Culture Collection, Rockville, MD, USA) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)-D5796 (Sigma-Aldrich, Tokyo, Japan) containing 10% fetal bovine serum (FBS) (Nichirei Bioscience, Tokyo, Japan) and 1% 100 U/mL penicillin/streptomycin (Sigma-Aldrich, Tokyo, Japan). Each assay described below was performed by culturing approximately $2.5 \times 10^5$ cells/well seeded in 24-well plates for 48 h. HepG2 cells were cultured at 37 °C with 5% CO$_2$.

2.2. Coffee Ingredients

Caffeinated coffee powder (Goldblend, Nestle Japan, Hyogo, Japan), decaffeinated coffee powder (Goldblend, Nestle, Hyogo, Japan), and CGA (Sigma-Aldrich, Tokyo, Japan) were used for the experiments. HepG2 cells were cultured in DMEM containing these ingredients (50, 100, and 200 µg/mL).

2.3. MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) Assay

HepG2 cells were cultured in DMEM containing coffee ingredients for 24 h, and after being washed with phosphate-buffered saline (PBS), they were incubated at 37 °C for 3 h in DMEM containing 0.5 mg/mL of MTT solution M5655 (thiazolyl blue tetrazolium bromide, Sigma-Aldrich, Tokyo, Japan). The MTT solution was removed and 0.04 N HCl/isopropanol was added, and 5 min later, the absorbance of the supernatant was measured (OD at 540 nm).

2.4. Enzyme Activity Measurement

Spectrophotometric analysis of the enzymes was performed as described [12,13]. Briefly, citrate synthase (CS): The cell solution was mixed with 100 mM Tris-HCl (pH 8.0), 10 mM DTNB (5,5′-dithio-bis-(2-nitrobenzoic acid)), and 2.5 mM acetyl-CoA, and the absorbance was measured using Biolis 24i (Tokyo-Boeki, Tokyo, Japan) (37 °C and 412 nm) after the addition of 50 mM oxaloacetic acid. Isocitrate dehydrogenase (IDH): The cell solution was mixed with 250 mM glycyglycine buffer (pH 7.4), 18 mM manganese chloride, and 20 mM nicotinamide adenine dinucleotide phosphate (NADP), and the absorbance was measured using Biolis 24i (37 °C, 340 nm) after the addition of 6.6 mM DL-isocitric acid. Malate dehydrogenase (MDH): The cell solution was mixed with 100 mM potassium phosphate buffer (pH 7.5) and 0.14 mM β-NADH, and the absorbance was measured using Biolis 24i (37 °C, 340 nm) after the addition of 7.6 mM oxaloacetic acid. Specific activity is defined as units per milligram protein and the data were presented as ratios of the untreated control.

2.5. Total RNA Extraction

Total RNA was isolated from HepG2 cells using the TRIzol reagent (Invitrogen Life Technologies, Tokyo, Japan). After culturing the cells under the above conditions, the medium was removed, the cells were washed with PBS, and 500 µL of TRIzol reagent was added and recovered. After standing at room temperature for 5 min, 0.1 mL of chloroform
was added and stirred, and the mixture was allowed to stand at room temperature for 2-3 min, then centrifuged at 4 \degree C and 12,000 \times g for 15 min. An amount of 125 \mu L of the upper layer was recovered and 250 \mu L of isopropanol was added. After standing at room temperature for 10 min, it was centrifuged at 12,000 \times g for 10 min at 4 \degree C. Cells were washed with 75\% ethanol, evaporated to dryness and dissolved in 30 \mu L of RNase-free water. RNA purity was assessed by the ratio of spectrophotometric absorbance at 260 and 280 nm (A_{260}/A_{280}) using a NanoDrop ND-1000 spectrophotometer (NanoDrop Products, Wilmington, DE, USA).

2.6. Quantitative Real-Time RT-PCR Analysis

Total RNA was used for mRNA analysis by quantitative real-time reverse transcription polymerase chain reaction (RT-PCR). Primers were designed using a web application (PRIMER3), and the sequence information is as follows: since the peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1a) gene has a long sequence, two primers were designed, both near the 3’ end and 5’ end. PGC1a (3’ end) sense: GCA-GAGAGGGAACTTTGCAC, antisense: ACAGCCATCAAGAAGGACA. PGC1a (5’ end) sense: CCTGTGGATGAAGACGGATT, antisense: TGGAGGAAGGACTAGCCTCA. SYBR Green EX (Takara Bio, Madison, WI, USA) was used for the PCR on a real-time PCR detection system (Takara Bio). The relative amounts of mRNA were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH sense: 5’-CGCCTGGAGAAACCTGCCAA-3’ anti-sense: 5’-GGAGACAACCTGGTCCTCAG-3’ mRNA levels and were expressed as fold-change values.

2.7. Proteomics Using Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Methods and Identification of Regulated Proteins

We performed differential proteomic analysis of HepG2 cells using iTRAQ, as described in our previous study [14]. iTRAQ is a non-gel-based technique used to quantify proteins from different sources in a single experiment. It uses isotope-coded covalent tags. Total protein was extracted using lysis buffer and separated by centrifugation at 12,000 \times g for 30 min at 4 \degree C. Protein concentrations were determined using the Bradford assay, and pooled proteins (20 \mu g) for each group (0, 50, 100 and 200 \mu g/mL of CGA treatment) were subjected to iTRAQ using the iTRAQ® kit, performed according to the manufacturer’s protocol (AB SCIEX, Framingham, MA, USA) with liquid chromatography–tandem mass spectrometry (LC/MS/MS) (TripleTOF TM 5600 + System with Eksigent nanoLC, AB SCIEX). Within an iTRAQ run, differentially changed proteins were determined by ProteinPilot software (AB SCIEX) based on the p-values, which are generated using the peptides used to quantitate the respective protein and give a measure of confidence (95\%). In this study, the data of proteins with significantly changed (p-value < 0.1) levels were uploaded to the statistical analysis tool Ingenuity Pathway Analysis (IPA), and enrichment analysis was performed [14].

2.8. Statistical Analysis

Data were presented as the mean ± standard error (SE). Statistical analysis was performed using a one-way analysis of variance (ANOVA) accompanied by a Tukey’s test. A p-value < 0.05 was considered statistically significant.

3. Results

3.1. The Effect of Coffee Powder and Chlorogenic Acid (CGA) on HepG2 Cell Viability

The potential effects of coffee powder and CGA on the viability and number of HepG2 cells were determined by MTT assay. HepG2 cells were incubated with DMEM containing caffeinated coffee powder, and the results are shown in Figure 1A. HepG2 cells were incubated with caffeinated coffee powder for 24 h, and the cell viability was significantly affected by the caffeinated coffee powder doses used (100 and 200 \mu g/mL). In addition,
CGA also increased the cell viability in a dose-dependent manner (Figure 1B) with the greatest effect at a dose of 200 µg/mL.

Figure 1. The effects of coffee powder and chlorogenic acid on hepatocellular carcinoma G2 (HepG2) cell viability. HepG2 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing coffee powder or chlorogenic acid for 24 h. The results of the 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay of cells cultured with (A) caffeinated coffee powder and (B) chlorogenic acid. The data are shown as mean ± SE (n = 4). * p < 0.05, ** p < 0.01 vs. control group.

3.2. Mitochondrial Enzyme Activity Analysis

Since HepG2 cell viability was increased by CGA, we next focused on the effect of CGA on the activities of three enzymes: IDH, CS, and MDH, which are key to the mitochondrial TCA cycle. The results revealed that the activities of all three enzymes were increased by CGA in a concentration-dependent manner (Figure 2). However, CGA addition did not alter the mRNA levels of these enzymes.

Figure 2. The effects of chlorogenic acid on mitochondrial enzyme activity in HepG2 cells. Confluent cultures of HepG2 cells were cultured with DMEM. Thereafter, different concentrations of chlorogenic acid were added and cells were cultured for 24 h. The enzyme activities of (A) isocitrate dehydrogenase (IDH), (B) citrate synthase (CS), and (C) malate dehydrogenase (MDH) were measured. The data are shown as mean ± SE (n = 4). * p < 0.05, ** p < 0.01 vs. control group.

3.3. Proteomics Using the iTRAQ Method

To explore the effect of CGA on HepG2 cells in a more comprehensive manner, we subjected the proteins extracted from the HepG2 cells treated, as described above, to a proteomic analysis using the iTRAQ method. Using this analysis, 2172 proteins were
identified, and 1409 proteins were successfully quantified. Among the identified proteins, 33, 80, and 64 proteins were significantly altered ($p < 0.1$) by CGA at 50, 100, and 200 µg/mL, respectively. Table 1 shows the 64 proteins whose expression was significantly changed by the addition of 200 µg/mL CGA. The data of the proteins whose levels were significantly altered were uploaded to the statistical analysis tool IPA, and the analysis revealed that the differentially expressed proteins were encoded by genes involved in pathways related to the glycolytic system (ALDOA, GAPDH, PGK1, and ENO1) and mitochondrial proteins (NDUFAF1, NDUFAF2, COX5B, ATP5B, and ATP5J). The increase in the levels of a protein involved in the glycolytic system suggests that the signals regulating glucose metabolism and the TCA cycle were enhanced by CGA (Table 1).

**Table 1.** Differentially expressed proteins between control and chlorogenic acid treatment groups by iTRAQ method.

| Protein | Name | Protein ID | 50 µg/mL | p-Value | 100 µg/mL | p-Value | 200 µg/mL | p-Value |
|---------|------|------------|----------|---------|-----------|---------|-----------|---------|
| SPTAN1  | Isoform 3 of Spectrin alpha chain, brain | Q13813-3 | 0.93 | 0.01 | 0.89 | 0.00 | 0.88 | 0.00 |
| HMGB1   | High mobility group protein B1 | P09429 | 0.59 | 0.00 | 0.42 | 0.00 | 0.55 | 0.00 |
| AHNAK   | Neuroblast differentiation-associated protein AHNAK | Q09666 | 0.96 | 0.36 | 0.83 | 0.00 | 0.86 | 0.00 |
| VSNL1   | Visin-in-like protein 1 | P62760 | 1.07 | 0.63 | 1.27 | 0.01 | 1.46 | 0.00 |
| PSAP    | Proactivator polypeptide | P07602 | 0.95 | 0.83 | 1.12 | 0.11 | 0.52 | 0.01 |
| HPCAL1  | Hippocalcin-like protein 1 | P37235 | 1.08 | 0.50 | 1.10 | 0.21 | 1.33 | 0.01 |
| ZC3H15  | Zinc finger CCCH domain-containing protein 15 | Q8WU90 | 0.85 | 0.19 | 0.72 | 0.00 | 0.82 | 0.01 |
| GAPDH   | Glyceraldehyde-3-phosphate dehydrogenase | P04406 | 1.30 | 0.16 | 1.22 | 0.00 | 1.38 | 0.01 |
| CPLX2   | Complexin-2 | Q6PUV4 | 1.34 | 0.14 | 1.33 | 0.01 | 1.70 | 0.01 |
| CFL1    | Cofilin-1 | P23528 | 0.47 | 0.01 | 0.96 | 0.54 | 0.66 | 0.01 |
| PGK1    | Phosphoglycerate kinase 1 | P00558 | 1.08 | 0.43 | 1.16 | 0.00 | 1.21 | 0.01 |
| KRT18   | Keratin, type I cytoskeletal 18 | P05783 | 1.20 | 0.02 | 1.17 | 0.02 | 1.21 | 0.02 |
| GLUD1   | Glutamate dehydrogenase 1, mitochondrial | P00367 | 1.08 | 0.23 | 1.07 | 0.12 | 1.12 | 0.02 |
| ATP5B   | ATP synthase subunit beta, mitochondrial | P06576 | 1.10 | 0.51 | 1.08 | 0.10 | 1.18 | 0.02 |
| IDH1    | Isocitrate dehydrogenase [NADP] cytoplasmic | O75874 | 1.11 | 0.34 | 1.16 | 0.01 | 1.21 | 0.03 |
| EIF3A   | Eukaryotic translation initiation factor 3 subunit A | Q14152 | 0.95 | 0.32 | 0.96 | 0.39 | 0.90 | 0.03 |
| TPR     | Nucleoprotein TPR | P12270 | 0.99 | 0.92 | 0.88 | 0.06 | 0.87 | 0.04 |
| PRDX6   | Peroxiredoxin-6 | P30041 | 0.83 | 0.11 | 0.96 | 0.54 | 0.88 | 0.04 |
| SRRT    | Serrate RNA effector molecule homolog | Q9BX5 | 0.79 | 0.12 | 0.99 | 0.95 | 0.81 | 0.05 |
| LM07    | LIM domain only protein 7 | Q8WW1 | 0.97 | 0.64 | 0.78 | 0.01 | 0.86 | 0.05 |
| NASP    | Nuclear autoantigenic sperm protein | P49321 | 0.84 | 0.07 | 0.87 | 0.07 | 0.85 | 0.05 |
| CALR    | Calreticulin | P27797 | 0.83 | 0.30 | 0.87 | 0.01 | 0.86 | 0.05 |
| PNPO    | Pyridoxine-5’-phosphate oxidase | Q9NV59 | 1.06 | 0.60 | 1.11 | 0.15 | 1.17 | 0.05 |
| HSFA5   | 78 kDa glucose-regulated protein | P11021 | 1.24 | 0.01 | 1.04 | 0.36 | 1.12 | 0.05 |
| CALD1   | Isoform HELA L-CAD II of Caldesmon | Q05682-5 | 0.81 | 0.04 | 0.75 | 0.02 | 0.82 | 0.05 |
| PTGES3  | Prostaglandin E synthase 3 | Q15185 | 0.36 | 0.07 | 0.92 | 0.78 | 0.67 | 0.05 |
| VDAC1   | Voltage-dependent anion-selective channel protein 1 | P21796 | 1.20 | 0.14 | 1.22 | 0.11 | 1.32 | 0.05 |
| WDR1    | WD repeat-containing protein 1 | O75083 | 1.11 | 0.38 | 1.14 | 0.05 | 1.19 | 0.05 |
| ENO1    | Alpha-enolase | P06733 | 1.26 | 0.14 | 1.17 | 0.02 | 1.28 | 0.05 |
| ATIC    | Bifunctional purine biosynthesis protein PURH | P31939 | 1.09 | 0.31 | 1.10 | 0.18 | 1.14 | 0.06 |
| Protein     | Name                                      | Protein ID | 50 µg/mL FC | 50 µg/mL p-Value | 100 µg/mL FC | 100 µg/mL p-Value | 200 µg/mL FC | 200 µg/mL p-Value |
|-------------|-------------------------------------------|------------|-------------|------------------|-------------|------------------|-------------|------------------|
| RPLP2       | 60S acidic ribosomal protein P2           | P05387     | 1.37        | 0.22             | 1.10        | 0.27             | 1.50        | 0.06             |
| HSPA9       | Stress-70 protein, mitochondrial          | P36866     | 0.85        | 0.22             | 0.91        | 0.30             | 0.85        | 0.06             |
| MYL6        | Myosin light polypeptide 6               | P60660     | 1.12        | 0.22             | 1.09        | 0.34             | 1.24        | 0.06             |
| FKB4P       | Peptidyl-prolyl cis-trans isomerase      | Q107290    | 1.16        | 0.25             | 1.11        | 0.33             | 1.23        | 0.06             |
| RPL23A      | 60S ribosomal protein L23a               | P62750     | 0.70        | 0.21             | 0.63        | 0.01             | 0.68        | 0.06             |
| TPDS2L2     | Tumor protein D54                        | O43399     | 0.87        | 0.27             | 0.75        | 0.02             | 0.82        | 0.06             |
| NIPSAP3A    | Protein NipSnap homolog 3A               | Q9UFN0     | 0.82        | 0.17             | 1.08        | 0.34             | 1.20        | 0.06             |
| TPM3        | Isoform TM30Nm of Tropomyosin alpha-3 chain | P06753-2   | 1.28        | 0.29             | 1.09        | 0.35             | 1.45        | 0.06             |
| NDUFA1B      | Acyl carrier protein, mitochondrial      | Q14561     | 1.35        | 0.33             | 1.30        | 0.11             | 1.87        | 0.06             |
| CYCS         | Cytochrome c                             | P99999     | 0.73        | 0.03             | 0.69        | 0.02             | 0.80        | 0.07             |
| PDLIM5       | PDZ and LIM domain protein 5             | Q96HC4     | 0.83        | 0.02             | 0.81        | 0.02             | 0.87        | 0.07             |
| ANPEP        | Aminopeptidase N                         | P15144     | 0.92        | 0.13             | 0.91        | 0.09             | 0.90        | 0.07             |
| ADK          | Adenosine kinase                         | P55263     | 0.81        | 0.15             | 0.91        | 0.36             | 0.79        | 0.07             |
| ATP5J        | ATP synthase-coupling factor 6, mitochondrial | P18859    | 2.10        | 0.12             | 1.46        | 0.23             | 2.29        | 0.08             |
| PCBD1        | Pterin-4-alpha-carbolamine dehydratase    | P61457     | 1.10        | 0.54             | 1.12        | 0.25             | 1.37        | 0.08             |
| UGDH         | UDP-glucose 6-dehydrogenase               | O60701     | 1.10        | 0.38             | 1.10        | 0.08             | 1.15        | 0.08             |
| NDUFAB2      | Mimitin, mitochondrial                   | Q8N183     | 1.18        | 0.22             | 1.11        | 0.37             | 1.31        | 0.08             |
| TTC1         | Tetratricopeptide repeat protein 1       | Q99614     | 1.01        | 0.89             | 1.05        | 0.56             | 1.17        | 0.09             |
| LASP1        | LIM and SH3 domain protein 1             | Q14847     | 0.94        | 0.60             | 0.98        | 0.82             | 1.25        | 0.09             |
| ALDOA        | Fructose-bisphosphatase aldolase A       | P04075     | 1.27        | 0.05             | 1.34        | 0.04             | 1.35        | 0.09             |
| FTH1         | Ferritin heavy chain                     | P02794     | 0.59        | 0.09             | 0.65        | 0.08             | 0.70        | 0.09             |
| ACAAA2       | 3-ketoacyl-CoA thiolase, mitochondrial   | P42765     | 1.18        | 0.11             | 1.13        | 0.34             | 1.21        | 0.09             |
| ENSA         | Isoform 8 of Alpha-endosulfine           | O43768-8   | 2.26        | 0.19             | 1.57        | 0.17             | 2.77        | 0.09             |
| BAT1         | Slicesosome RNA helicase BAT1             | Q13838     | 0.76        | 0.22             | 1.04        | 0.62             | 0.76        | 0.09             |
| RPL13        | 60S ribosomal protein L13                | P26373     | 1.24        | 0.22             | 1.16        | 0.68             | 1.24        | 0.09             |
| UGTT1        | UDP-glucose:glycoprotein glucosyltransferase 1 | Q9NYU2    | 1.00        | 0.99             | 0.83        | 0.06             | 0.88        | 0.09             |
| UBQLN1       | Ubiquilin-1                              | Q9UMX0     | 1.11        | 0.28             | 1.13        | 0.22             | 1.21        | 0.10             |
| MESDC2       | LDLR chaperone MESD                      | Q14696     | 0.83        | 0.12             | 0.72        | 0.06             | 0.82        | 0.10             |
| NUTF2        | Nuclear transport factor 2               | P61970     | 1.37        | 0.05             | 1.58        | 0.01             | 1.42        | 0.10             |
| STRAP        | Serine-threonine kinase receptor-associated protein | Q9Y3F4  | 1.16        | 0.12             | 1.25        | 0.04             | 1.18        | 0.10             |
| COX5B        | Cytochrome c oxidase subunit 5B, mitochondrial | P10606   | 1.09        | 0.75             | 1.06        | 0.61             | 1.34        | 0.10             |

Differentially expressed proteins (p < 0.1) were treated with 50, 100, and 200 µg/mL of chlorogenic acid. FC: fold change. iTRAQ: isobaric tags for relative and absolute quantitation.

4. Discussion

The effects of coffee ingredients and coffee polyphenols on cultured hepatic cells have been examined in many studies. First, to evaluate the validity of the study design in which coffee ingredients were directly added to the culture medium, we referenced a previous study that reported the concentrations of coffee ingredients in the blood after the participants drank coffee [15]. The authors reported that the maximum blood concentration of CGA was 5 µM (1.77 µg/mL) after the participants orally ingested 40 g of coffee powder. Another study revealed that after participants drank a cup of coffee, the concentration of the sum of CGA metabolites (including dihydrocaffeic acid and dihydroferulic acid) in their blood was approximately 1 µM [16].

Furthermore, the effect of chlorogenic acid directly added to cultured hepatic cells on lipid metabolism was reported by Liu et al. [17]. In that study, the effects of chlorogenic acid, caffeic acid, and ferulic acid (20–100 µg/mL, respectively) on oleic acid-induced hepatosteatosis were examined, and these coffee polyphenols were found to inhibit the
accumulation of lipids in hepatic cells. These studies suggest that coffee polyphenols in the 
blood could exert physiological actions. Therefore, the present study design in which coffee 
ingredients were directly added into the culture medium aimed to mimic the conditions 
after a long-term coffee consumption to some extent.

We performed this study to further investigate the effects of coffee and CGA on energy 
metabolism in an in vitro experiment using HepG2 cells. Considering the results of the 
MTT assay, we found that coffee powder and CGA treatment increased cell viability and 
cell numbers (Figure 1); moreover, our results indicate that CGA at the concentrations 
tested is not cytotoxic to HepG2 cells, but rather exerts a slight proliferative effect. In 
addition, PGC1α is reported to be a genetic marker for mitochondrial biogenesis, so we 
measured its expression by analyzing total RNA extracted from HepG2 cells. The results 
showed no difference in PGC1α levels with or without the addition of CGA (Figure S1). 
Therefore, further studies are needed to confirm whether the proliferative effect of CGA is 
related to mitochondrial activity.

Based on our enzyme activity measurement, CGA increased the activities of three 
key enzymes, CS, IDH, and MDH (Figure 2). However, the mRNA expression levels of 
the three genes were not affected by CGA, as observed in the quantitative PCR analysis 
(data not shown), thus, we speculated that CGA influences the activities of enzymes and 
not their mRNA levels. Nevertheless, further investigation on the changes in the different 
isoforms and the time-dependent mRNA expression of the three enzymes, is warranted.

To obtain a more comprehensive view of the mechanism underlying this phenomenon, 
we performed a proteomic analysis using the iTRAQ method. The enrichment analysis 
of the proteins whose levels were differentially altered by the addition of 200 µg/mL of 
CGA revealed that these proteins were either involved in pathways of the glycolytic system 
(ALDOA, GAPDH, PGK1, and ENO1) or mitochondrial proteins (NDUFAB1, DUFAB2, 
COX5B, ATP5B, and ATP5J). The increased levels of proteins involved in the glycolytic 
system suggest that signals between glucose metabolism and the TCA cycle are enhanced 
by CGA. NADH dehydrogenases (NDUFAB1 and NDUFAB2) are the first enzymes of the 
electron transport system in mitochondria, and COX5B is an enzyme that is also known to 
be involved in the electron transport system. ATP synthases (ATP5B, ATP5J) synthesize 
ATP from the electron transport system in the mitochondria. The increased levels of these 
mitochondrial proteins suggest that CGA not only enhances the TCA cycle but also other 
mitochondrial activities, including the electron transport chain and ATP synthesis.

However, additional studies are needed to pinpoint the potential transcriptional factors 
involved in these processes and clarify the detailed mechanisms impacting the regulation 
of NADH dehydrogenases and ATP synthases. Although HepG2 cells are widely used 
to study hepatocyte metabolism as well as hepatocyte physiology, the results presented 
here should be interpreted with caution owing to their cancerous characteristics. Further 
studies of primary cell models are needed to confirm the effect of CGA and coffee extract 
on energy metabolism.

Together, the results of the present in vitro study provide novel insights into the 
mechanism whereby CGA enhances energy metabolism, that is, by increasing hepatic 
mitochondrial activities, including the TCA cycle, electron transport, and ATP synthesis 
(Figure 3). Our findings demonstrated that CGA induced hepatic alterations in mitochon-
drial enzyme activities, and increased expression of proteins involved in the glycolytic 
system, electron transport system, and ATP synthesis in the mitochondria. This proposed 
mechanism could be a key aspect in elucidating the beneficial effects of coffee intake.
Figure 3. A schematic representation of the proposed mechanism underlying the effects of chlorogenic acid on metabolism as determined by the present in vitro study using HepG2 cells.

5. Conclusions

In summary, we examined the effects of CGA on energy metabolism in vitro. We propose a mechanism whereby CGA enhances energy metabolism by increasing hepatic mitochondrial activity, including the TCA cycle, glycolysis, electron transport, and ATP synthesis. This study suggests that these alterations provide important insights into the beneficial effects of coffee intake.

Supplementary Materials: The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/nu14081676/s1, Figure S1: The effects of chlorogenic acid on the mRNA expression of PGC1α. HepG2 cells were cultured in DMEM containing chlorogenic acid (200 µg/mL), and the mRNA expression at each time point was measured by RT-PCR. A: Using the primer designed near the 3′ end. B: Using the primer designed near the 5′ end.

Author Contributions: Conceptualization, H.K. and S.T.; methodology, S.T. and H.J.; formal analysis, S.T.; investigation, X.L., K.S. and H.J.; data curation, S.T., K.S. and H.J.; writing—original draft preparation, S.T. and X.L.; writing—review and editing, H.J. and H.K.; project administration, H.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research was partly funded by a grant from the All Japan Coffee Association.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Van Dam, R.M.; Hu, F.B. Coffee consumption and risk of type 2 diabetes: A systematic review. JAMA 2005, 294, 97–104. [CrossRef] [PubMed]
2. Carlsson, S.; Hammar, N.; Grill, V.; Kaprio, J. Coffee consumption and risk of type 2 diabetes in Finnish twins. Int. J. Epidemiol. 2004, 33, 616–617. [CrossRef] [PubMed]
3. Huxley, R.; Lee, C.M.; Barzi, F.; Timmermeister, L.; Czernichow, S.; Perkovic, V.; Grobbee, D.E.; Batty, D.; Woodward, M. Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: A systematic review with meta-analysis. Arch. Intern. Med. 2009, 169, 2053–2063. [CrossRef] [PubMed]
4. Larsson, S.C.; Wolk, A. Coffee consumption and risk of liver cancer: A meta-analysis. *Gastroenterology* 2007, 132, 1740–1745. [CrossRef] [PubMed]

5. Li, D.; Na, X.; Wang, H.; Wang, C.; Yuan, Z.; Zhu, B.W.; Tan, M. The effects of carbon dots produced by the Maillard reaction on the HepG2 cell substance and energy metabolism. *Food Funct.* 2020, 11, 6487–6495. [CrossRef] [PubMed]

6. Vijayakumar, K.; Rengarajan, R.L.; Radhakrishnan, R.; Mathew, S.; Qadri, I.; Vijaya Anand, A. Psidium guajava Leaf Extracts and Their Quercetin Protect HepG2 Cell Lines Against CCL4 Induced Cytotoxicity. *Indian J. Clin. Biochem.* 2019, 34, 324–329. [CrossRef] [PubMed]

7. Riedel, A.; Hochkogler, C.M.; Lang, R.; Bytof, G.; Lantz, I.; Hofmann, T.; Somoza, V. N-methylpyridinium, a degradation product of trigonelline upon coffee roasting, stimulates respiratory activity and promotes glucose utilization in HepG2 cells. *Food Funct.* 2014, 5, 454–462. [CrossRef] [PubMed]

8. Vaynshteyn, D.; Jeong, H. Caffeine induces CYP1A2 expression in rat hepatocytes but not in human hepatocytes. *Drug Metab. Lett.* 2012, 6, 116–119. [CrossRef] [PubMed]

9. Kalthoff, S.; Ehmer, U.; Freiberg, N.; Manns, M.P.; Strassburg, C.P. Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. *Gastroenterology* 2010, 139, 1699–1710.e2. [CrossRef] [PubMed]

10. Takahashi, S.; Saito, K.; Jia, H.; Kato, H. An integrated multi-omics study revealed metabolic alterations underlying the effects of coffee consumption. *PloS ONE* 2014, 9, e91134. [CrossRef] [PubMed]

11. Takahashi, S.; Egashira, K.; Saito, K.; Jia, H.J.; Abe, K.; Kato, H. Coffee intake down-regulates the hepatic gene expression of peroxisome proliferator-activated receptor gamma in C57BL/6J mice fed a high-fat diet. *J. Funct. Foods* 2014, 6, 157–167. [CrossRef]

12. Sauer, S.W.; Okun, J.G.; Schwab, M.A.; Crnic, L.R.; Hoffmann, G.F.; Goodman, S.I.; Koeller, D.M.; Kolker, S. Bioenergetics in glutaryl-coenzyme A dehydrogenase deficiency: A role for glutaryl-coenzyme A. *J. Biol. Chem.* 2005, 280, 21830–21836. [CrossRef] [PubMed]

13. Shepherd, D.; Garland, P.B. [2] Citrate synthase from rat liver: [EC 4.1.3.7 Citrate oxaloacetate-lyase (CoA-acetylating)]. In *Methods in Enzymology*; Academic Press: Salt Lake City, UT, USA, 1969; Volume 13, pp. 11–16. [CrossRef]

14. Jia, H.; Wen, Y.; Aw, W.; Saito, K.; Kato, H. Ameliorating Effects of Coriander on Gastrocnemius Muscles Undergoing Precachexia in a Rat Model of Rheumatoid Arthritis: A Proteomics Analysis. *Nutrients* 2021, 13, 4011. [CrossRef] [PubMed]

15. Monteiro, M.; Farah, A.; Perrone, D.; Trugo, L.C.; Donangelo, C. Chlorogenic acid compounds from coffee are differentially absorbed and metabolized in humans. *J. Nutr.* 2007, 137, 2196–2201. [CrossRef] [PubMed]

16. Williamson, G.; Dionisi, F.; Renouf, M. Flavanols from green tea and phenolic acids from coffee: Critical quantitative evaluation of the pharmacokinetic data in humans after consumption of single doses of beverages. *Mol. Nutr. Food Res.* 2011, 55, 864–873. [CrossRef] [PubMed]

17. Liu, Y.; Wang, D.; Zhang, D.; Lv, Y.; Wei, Y.; Wu, W.; Zhou, F.; Tang, M.; Mao, T.; Li, M.; et al. Inhibitory effect of blueberry polyphenolic compounds on oleic acid-induced hepatic steatosis in vitro. *J. Agric. Food Chem.* 2011, 59, 12254–12263. [CrossRef] [PubMed]